HealthAffairs cited the article “Rethinking Access to Immunizations After COVID-19: Assuring a Vaccine Safety Net for All Americans,” authored by Richard H. Hughes, IV, Member of the Firm in the Health Care & Life Sciences practice, in the firm’s Washington, DC, office, in “A Twenty-First Century 'Vaccines for Children' Program.”

Following is an excerpt:

In his excellent Forefront article on legislative reforms to strengthen the Vaccines for Children (VFC) program, which is entering its third decade, Richard Hughes IV underscores the importance of updating the law to protect people of all ages. Another priority—one that can be addressed under existing law and without congressional action—is ensuring that as the science evolves, the program continues to ensure that children benefit from the full range of modern preventive therapies against transmissible, potentially deadly childhood disease.

The recommendations of the Advisory Committee on Immunization Practices (ACIP) set the nation’s immunization standards. The ACIP has already begun to align its recommendations to encompass not only traditional vaccines, which work by building protection over time, but also monoclonal antibodies (mAbs), which confer immediate protection against communicable disease. Both types of products confer immunity; as a result, the ACIP’s decision that newer immunization technologies fall within the scope of its charter authority is not only consistent with, but arguably required by, its 1964 founding mission—to advise the Surgeon General “regarding the most effective application in public health practice of specific preventive agents which may be applied in communicable disease control.”

The ACIP is now about to begin formal consideration of immunization recommendations for mAbs designed to prevent respiratory syncytial virus (RSV). A particularly vicious virus that strikes in infancy and early childhood, RSV can trigger serious illness in children; for infants, it can be life-threatening. RSV tends to be cyclical, striking from late fall through early spring and is the most common cause of deadly pneumonia and bronchitis in babies. Most children will experience RSV before they turn two, and RSV strikes millions of children worldwide.

Beyond causing widespread, costly sickness, RSV kills an estimated 500–1,000 children in the US annually. Death from RSV is an especially serious risk for premature babies and those younger than six months of age, children younger than two with chronic lung disease or congenital heart disease, children with weakened immune systems, and those with neuromuscular disorders, including children who experience difficulty swallowing or clearing mucus.

Jump to Page

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.